Q BioMed Inc. (QBIO)
OTCMKTS: QBIO · Delayed Price · USD
0.0002
0.00 (0.00%)
Apr 18, 2024, 2:32 PM EDT - Market closed
Q BioMed Revenue
Q BioMed had revenue of $15.04K in the twelve months ending August 31, 2023, down -96.01% year-over-year. In the fiscal year ending November 30, 2022, Q BioMed had annual revenue of $284.35K with 45.38% growth.
Revenue (ttm)
$15.04K
Revenue Growth
-96.01%
P/S Ratio
1.93
Revenue / Employee
$5,012
Employees
3
Market Cap
29.02K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2022 | 284.35K | 88.76K | 45.38% |
Nov 30, 2021 | 195.60K | 165.60K | 551.99% |
Nov 30, 2020 | 30.00K | - | - |
Nov 30, 2019 | 0 | - | - |
Nov 30, 2018 | 0 | - | - |
Nov 30, 2017 | 0 | - | - |
Nov 30, 2016 | 0 | - | - |
Nov 30, 2015 | 0 | - | - |
Nov 30, 2014 | 0 | - | - |
Nov 30, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
QBIO News
- 11 months ago - Q BioMed Inc. Provides Update to Shareholders - PRNewsWire
- 1 year ago - Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe - PRNewsWire
- 1 year ago - Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office - PRNewsWire
- 1 year ago - Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC. - PRNewsWire
- 1 year ago - Q BIOMED PROVIDES SHAREHOLDER UPDATE - PRNewsWire
- 1 year ago - Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER - PRNewsWire
- 1 year ago - Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc. - Accesswire
- 2 years ago - Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets - PRNewsWire